Theragenics acquires Core Oncology’s prostate brachytherapy customer base
Theragenics (NYSE:TGX) announced its acquisition of Core Oncology’s prostate brachytherapy customer base. Terms of the deal are an earnout equal to one time the revenue generated from the acquired customers over a one year period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold.
Theragenics paid $3.8 million in cash as prepayment of a portion of the earn-out.
Theragenics acquires Core Oncology’s prostate brachytherapy customer base
Theragenics (NYSE:TGX) announced its acquisition of Core Oncology’s prostate brachytherapy customer base. Terms of the deal are an earnout equal to one time the revenue generated from the acquired customers over a one year period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold.
Theragenics paid $3.8 million in cash as prepayment of a portion of the earn-out.
Comments are closed.